The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
Efficacy was evaluated in the open-label, active-controlled, phase 3 APOLLO trial (ClinicalTrials.gov Identifier: NCT03180736). Findings from the study were presented at the 2020 annual meeting of the American Society of Hematology